Journal of Pathogens

Journal of Pathogens / 2011 / Article

Research Article | Open Access

Volume 2011 |Article ID 128318 | 37 pages | https://doi.org/10.4061/2011/128318

Schizophrenia: A Pathogenetic Autoimmune Disease Caused by Viruses and Pathogens and Dependent on Genes

Academic Editor: Man W. Tan
Received30 Nov 2010
Accepted25 Feb 2011
Published26 May 2011

Abstract

Many genes have been implicated in schizophrenia as have viral prenatal or adult infections and toxoplasmosis or Lyme disease. Several autoantigens also target key pathology-related proteins. These factors are interrelated. Susceptibility genes encode for proteins homologous to those of the pathogens while the autoantigens are homologous to pathogens' proteins, suggesting that the risk-promoting effects of genes and risk factors are conditional upon each other, and dependent upon protein matching between pathogen and susceptibility gene products. Pathogens' proteins may act as dummy ligands, decoy receptors, or via interactome interference. Many such proteins are immunogenic suggesting that antibody mediated knockdown of multiple schizophrenia gene products could contribute to the disease, explaining the immune activation in the brain and lymphocytes in schizophrenia, and the preponderance of immune-related gene variants in the schizophrenia genome. Schizophrenia may thus be a “pathogenetic” autoimmune disorder, caused by pathogens, genes, and the immune system acting together, and perhaps preventable by pathogen elimination, or curable by the removal of culpable antibodies and antigens.

1. Introduction

Over 600 genes have been implicated in schizophrenia in association studies, supporting the contention that multiple genes of small effect contribute to this condition [1, 2] (see http://www.polygenicpathways.co.uk/schizgenesandfunc.htm for association references). These genes cluster together in clearly defined signalling networks related to the diverse subpathologies of schizophrenia [37]. Epistasis between genes within these same signalling networks markedly affects the degree of risk-promotion [810], in part, explaining the inconsistency in genetic association studies.

Schizophrenia has also been associated with prenatal complications including maternal rubella (German measles) [11], influenza [12, 13], Varicella zoster (chicken pox) [14], Herpes (HSV-2) [15], common cold infection with fever [16], or poliovirus infection [17] while in childhood or adulthood, coxsackie virus infection (in neonates [18]) or Lyme disease (vectored by the Ixodes tick and Borrelia Burgdorferri) or Toxoplasmosis have been reported as risk factors [19, 20] (see Table 1). The human endogenous retrovirus, HERV-W, has also been implicated in schizophrenia [21]. A number of schizophrenia-related genes are implicated in the life cycles of these pathogens, suggesting an interplay between genes and risk factors [22].


Pre- and perinatal maternal infectionJuvenile (in offspring)Adult

Rubella (first trimester) [76]:
Influenza (first trimester) [13]
Influenza or common cold with fever (second trimester) [16]
Mumps or cytomegalovirus infection
(0–12 years old) [77]
HSV-1 seropositivity related to grey matter volume [78]

Poliovirus (second trimester) [17]Coxsackie B5 infection perinatally [18]HSV-1 (in Afro-Americans) or HHV-6 seropositivity: Inverse correlation with HSV-2 and cytomegalovirus [79]

Measles, Varicella zoster or polio (seropositivity at birth) [14]Childhood meningitis (0–4 years old) [80]Borna disease virus seropositivty [81]

HSV-2 (antibodies assayed at the end of pregnancy) [82]Coronavirus seropositivity [83]

Influenza B (seropositivity at birth) [84]Elevated retrovirus HERV-W transcripts [85]

Toxoplasmosis (antibodies during pregnancy) [86]Measles virus seropositivity [87]

Hepatitis C [38]

Toxoplasmosis [88]

Correlation with the incidence of Lyme disease (Borrelia) [20]

Many schizophrenia genes relate to the immune network [5, 6, 22, 23]. Immune activation is also observed in the schizophrenic brain [24, 25] or in lymphocytes [2629]. A number of autoantigens/autoantibodies to key schizophrenia-related proteins have also been reported. These include dopamine, serotonin, acetylcholine, and NMDA receptors; inter alia (Table 2). Maternal immune activation in animal models has also been shown to generate phenotypes relevant to schizophrenia in the offspring [30].


Autoantigen referencePathogens

CHRNA7 Nicotinic cholinergic receptor [89]128318.table.201
CHRM1 Muscarinic cholinergic receptor [90]128318.table.202
DRD2 Dopamine receptor [82]128318.table.203
GRIN1 NMDA receptor subunit [91]128318.table.204
ELANE Leukocyte elastase [92]128318.table.205
OPRM1 Opioid receptor [93]128318.table.206
NGF Nerve growth factor [92]128318.table.207
HTR1A Serotonin receptor [93]128318.table.208
HSP60 Heat shock protein 60 [94]128318.table.209
HSPA12A Heat shock protein 70 [95]128318.table.2010
HSP90 Heat shock protein 90 [95]128318.table.2011
PAM/MYC [94]128318.table.2012
S100B [96]128318.table.2013
STRN Striatin [96]128318.table.2014

As shown below, genes, risk factors, and immunity can be linked together forming a unifying pathway whose elements are interdependent. Dysfunction of this network which is conditional upon interactions between its three branches may be responsible for schizophrenia.

2. Methods

The human herpesvirus 2 genome (NC_001798) as well as those of the rhinovirus (NC_001490), rubella (NC_001545.1) and Varicella zoster (NC_001348.1) and HERV-W (NP_055405.3: env polyprotein) viruses, Borrelia Burgdorferri (NC_011728) and T. Gondii (NC_001799: Partial genome) were screened against the human proteome using the NCBI BLAST server and the Entrez query filter “schizophrenia”. The HERV-W, influenza, HSV-2 and rubella viruses were also screened unfiltered (Translated pathogen genome versus human proteins: BlastX) [31]. The BLAST algorithm detects overall homology between entire gene or protein sequences, and it is necessary to set parameters to low significance levels in order to detect short intraprotein consensus homology. The parameters used were: Expect 20,000, value = 100,000; matrix PAM30. The original BLAST results are stocked at http://www.polygenicpathways.co.uk/blasts.htm. Information for all abbreviations is available at this site, provided by the NextBio highlighting service.

BLAST files were scanned by an online tag cloud generator producing tags sized according to gene word occurrences http://www.tagcloud-generator.com/generator.php#anker. Word occurrences were counted using a “Highlightall add-in” for Firefox https://addons.mozilla.org/en-US/firefox/addon/4240/.

Antigenicity (B-cell epitope prediction) was estimated using the BepiPred server http://www.cbs.dtu.dk/services/BepiPred/ [32] (Table 4).

Kegg pathway analysis [33] of 632 schizophrenia susceptibility gene candidates was performed using Kegg mapper http://www.genome.jp/kegg/tool/color_pathway.html. The results of this analysis are available at http://www.polygenicpathways.co.uk/keggszgenes.htm. Venn diagrams were constructed online at http://www.bioinformatics.org/gvenn/index.htm [34].

Genes and risk factors with at least one positive association are included in this study. Although certain genes and risk factors are clearly more important than others, and problems of replication in both gene and risk factor studies abound, gene, gene, and gene/environment interactions may explain some of the heterogeneity. For example many schizophrenia-related genes are involved in the life cycle of T. Gondii, but may be irrelevant if this pathogen is not encountered. Similarly T. Gondii infection may have little effect is such gene variants are not present. Pathway analyses of genome wide association data, and previous studies, are showing that the risk-promoting effects of many genes in similar pathways are better predictors of risk, than when treating each gene in isolation (see Section 1). Although some of these factors may be false positives, many genes and risk factors may have a role to play in certain conditions, but the greater import of genes such as DISC1 or neuregulin is recognised.

3. Results

Pictograms of selected BLAST results are shown in Figure 1. The initial sweep of unfiltered BLASTs returned 125–304 hits, but this number was markedly increased when using the filter “schizophrenia” (14,088 Hits for HSV-2). For unfiltered sweeps, the viral homologues are longer, while the filtered sweeps return shorter contiguous sequences nevertheless including multiple matches of pentapeptides or more.

Viral-human matches are characterised by short contiguous amino acid matches of 5 or more amino acids, that are identical in viral and human proteins, defined as vatches (viral matches). These are exemplified, for DISC1 in Figure 2. Hexapeptide matches have also been described for the influenza H5N1 virus and this study also highlighted homologies with DISC1, reelin and neurexin, inter alia [35]. The entire length of a human protein can be composed of many overlapping, intercalated vatches, related to multiple viral species. However, the viral spectrum is distinct for each protein as shown in Figure 3 for DISC1, neuregulin, the D2 dopamine receptor and transcription factor 4. Each is homologous to proteins from a large spectrum of viruses, but this spectrum is distinct for each protein. Interestingly, all are homologous to proteins from the hepatitis C virus. Several studies have noted that Hepatitis C infection is associated with schizophrenia, but this has generally been interpreted in terms of a schizophrenia life style that favours infection, rather than viewing Hepatitis C as a risk-promoting factor [3639]. These data may challenge this assumption.

All of the pathogens implicated in schizophrenia express proteins with homology to multiple schizophrenia susceptibility gene products (Table 3). The profile of each individual pathogen is again specific for different types of gene product, but all target key members of the schizophrenia network including dopamine, serotonin and glutamate receptors as well as neuregulin and growth-related or DISC1 related pathways. This is the case even when no filter is used. Interestingly, both the rubella and the influenza viruses target members of the translation initiation complex, which has been implicated in myelination and oligodendrocyte survival [4, 40]. Oligodendrocyte cell loss and myelination defects are prominent in the schizophrenic brain [4144].


128318.table.0001a
128318.table.0001b
128318.table.0002
128318.table.0003
128318.table.0004
128318.table.0005
128318.table.0006
128318.table.0007
128318.table.0008
128318.table.0009
128318.table.00010
128318.table.00011
128318.table.00012
128318.table.00013
128318.table.00014
128318.table.00015


DISC1 partner gene symbolProtein nameViral binder

ACTG1Actin, cytoplasmic 2HIV-1 [97] HSV1 [98]
ACTN2Actinin, alpha 2Hepatitis C [99]
AKAP9A-kinase anchor protein 9Epstein-Barr [97]
ATF4Cyclic AMP-dependent transcription factor ATF-4HSV1 [98]
ATF5Cyclic AMP-dependent transcription factor ATF-5HTLV1 [100]
BICD1Protein bicaudal D homolog 1Cytomegalovirus [101]
C14orf135Uncharacterized protein C14orf135 precursorHepatitis C [102]
DCTN1Dynactin-1HSV1 [98]
DCTN2Dynactin subunit 2Dynactins are involved in the transport of the adenoviruses, HSV-1, the hantaan virus, HTLV-1 and the poliovirus [103108]
DNAJC7DnaJ homolog subfamily C member 7Part of a complex forming the coxsackie virus receptor [109]
DYNC1H1Dynein heavy chain, cytosolicAdenovirus (in a complex with dynactin and NDEL1) [110]
EEF2Elongation factor 2Epstein Barr [111]
EIF3S3Eukaryotic translation initiation factor 3 subunit 3Hepatitis C [112]
FEZ1Fasciculation and elongation protein zeta 1 (zygin I)JC Polyomavirus [113]
HERC2HECT domain and RCC1-like domain-containing protein 2Papillomavirus 16 [114]
KIF3CKinesin-like protein KIF3CHIV-1 [115]
MATR3Matrin-3HSV1 [98]
NDEL1Nuclear distribution protein nudE-like 1Part of a complex involved in Adenovirus transport (with dynactin and cytoplasmic dynein) [110]
PAFAH1B1Platelet-activating factor acetylhydrolase IB subunit alphaBinds to Poliovirus P3 protein and HIV-1 Tat [116, 117]
PCNTPericentrinInvolved in the microtubular transport of the adenovirus [118]
PGK1Phosphoglycerate kinase 1 Epstein-Barr [119]
SMARCE1SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1HSV-1 [97]
STX18Syntaxin-18 Papillomavirus [119]
TNKSTankyrase-1 Epstein-Barr [120]
TUBBTubulin beta chain Epstein-Barr [119]
YWHAE14-3-3 protein epsilonHepatitis C [97] :  L : Epstein-Barr [119]
YWHAQ14-3-3 protein thetaHIV [97] HSV1 [98]
YWHAZ14-3-3 protein zeta/deltaHSV1 [98] : Epstein-Barr [119]

The degree of overlap between the rubella, HERV and influenza viruses and schizophrenia gene products is shown by the Venn diagrams in Figure 3. All but one schizophrenia gene product was covered by various permutations and similar data were recovered for other pathogens. All schizophrenia gene products ( ) were homologous to proteins expressed by one or more of these pathogens. However, only 16 proteins were common to all 8 pathogens (Figure 3). These included neuregulin (NRG1) and DISC1, dopamine (DRD5), glutamate (GRIA4, GRID1, GRM3, GRM7) GABA (GABBR1) and serotonin (HTR7) receptors, a presynaptic protein regulating glutamate release (synapsin SYN3) and HOMER2, a member of the postsynaptic scaffold, all of which are key elements relating to the pathology of schizophrenia.

Other proteins within this class included neurocan (CSPG5), a chondroitin sulphate proteoglycan expressed in oligodendrocytes that inhibits neurite outgrowth and regulates axonal growth [4547]. It is also involved thalamocortical projection development [48]. ARHGEF10 is a rho Guanine-nucleotide exchange factor that controls myelination [49]. NDUFV2 is a subunit of the mitochondrial respiratory chain and its protein expression levels are reduced in the frontal cortex and striatum in schizophrenia [50]. PPP3CC Calcineurin gamma (PPP3CC) plays a role in dopamine receptor signalling [51, 52]. Calcineurin knockout mice show defects in prepulse inhibition and other phenotypes related to schizophrenia [53]. Calcineurin is highly expressed in the immune system and regulates the expression of numerous cytokines [54]. MAP6 is a microtubule protein that controls synaptic organisation, in particular of glutamatergic synapses where it controls the expression of the glutamate transporter and presynaptic genes, synaptophysin and GAP-43, spinophilin and MAP2. [55, 56] KCNH2 is a potassium channel that plays a role in the development of neural crest cells [57] and in lymphocyte proliferation [58]. PRSS16 is a serine protease involved in autoimmunity and the presentation of self-antigens within the thymus [59].

So, by a random bioinformatics process, trawling the entire human proteome, asking simply which proteins are homologous to those of the pathogens implicated in schizophrenia, we arrive at a small set of proteins related to synaptic and dendritic function, myelination, neuregulin and DISC1 pathways, glutamate, dopamine, GABA and serotonin transmission, and immune regulation that are the cornerstones of schizophrenia pathology [3, 6062].

3.1. Autoantigens in Schizophrenia

Many autoantibodies have been reported in schizophrenia. The pathogens implicated in schizophrenia also express proteins that are homologous to these autoantigens. Again the profile of each autoantigen or pathogen is distinct as shown in Table 2.

3.2. DISC1

DISC1 is a key “hub gene” in schizophrenia linked, via its interactome, to many other schizophrenia susceptibility gene products [3, 6366]. Its viral homology is illustrated in Figure 2. The Varicella virus is homologous to DISC1 in several regions, over its entire length, many matches in regions of high immunogenicity. These figures illustrate the types of matches seen in other proteins and shows that the vatches are often part of larger gapped consensus sequences. Interestingly, Varicella infection also results in the production of antibodies to pericentrin, a DISC1 binding partner [67].

DISC1 is a highly immunogenic protein, as predicted by B-cell epitope prediction (Figure 4). Autoantibodies to DISC1 have not been reported in schizophrenia. However, the viral risk factors implicated in schizophrenia express proteins that are homologous to the highly antigenic regions of the DISC1 protein, as shown in Figure 2. These viral proteins are equally antigenic and antiviral antibodies might also thus be expected to target multiple regions of the DISC1 protein.

3.3. Viral Proteins Are Part of the DISC1 Interactome

DISC1 and many of its binding partners, or other members of its interactome, contain vatches that are homologous to proteins expressed by the Rubella virus (Figure 5). (Other viruses also display this property, although the interactome members targeted are distinct, and specific for each virus (see http://www.polygenicpathways.co.uk/vatches.htm). Upon infection, viruses might therefore be considered as extraneous spurs to these types of protein/protein networks, and are likely to markedly affect their integrity. Indeed, several viruses, including herpes simplex, hepatitis C, Epstein-Barr, the cytomegalovirus, adenovirus and Coxsackie virus are known to bind to DISC1 interaction partners (Table 4).

3.4. Viral DNA within the Human Genome

The insertion of viral DNA into the human genome had until recently been thought to be the preserve of retroviruses. However the incorporation of DNA into mammalian genomes has recently been demonstrated on a large scale for both RNA and DNA viruses. Viral integration may be mediated by nonhomologous recombination with chromosomal DNA or, in the case of RNA viruses, by interactions with host chromosomal retrotransposons [68, 69]. It has also been shown the herpes virus HHV-6 can be transmitted from parent to child via chromosomal integration [70]. The BLAST analyses of the viruses detailed in this paper, and of others at http://www.polygenicpathways.co.uk/blasts.htm clearly show that viral DNA from many species is present within the human genome. This viral homology may well cover the entire human genome. For example, a Blast of human chromosome 10 against all viral genomes (almost 3,000 viral forms) yielded 119,857 hits with entire coverage of 135.5 million bases. Viral DNA is thus both inter and intragenic (Figure 1). It has been proposed that retroviral integration, into paternal and maternal gene lines, inserting several genes at once and effectively creating a new being, is responsible for evolutionary saccades [71]. The fact that RNA and DNA nonretroviruses can also be so incorporated has important implications in this area.

The HSV-2 virus is homologous to several dopamine receptors and the BLAST pictogram shows how the same virus provokes repeating patterns in the human proteome (Figure 6). The same is true of the Herpes simplex virus (HSV-1) which is homologous to multiple lipoprotein receptors as well as to multiple kinases or of the cytomegalovirus which expresses proteins homologous to many chemokine receptors (see http://www.polygenicpathways.co.uk/blasts.htm). One interpretation of this, given the ability of chromosomal integration, is that repeated viral visits to the human genome over millions of years are responsible for the creation of gene families.

It is also possible that viral/human homology reflects convergent viral evolution, although this is difficult to reconcile with the presence of viral DNA in intergenic regions, for which there would be little evolutionary drive or selective pressure. It is also plausible that a bidirectional transfer of human and viral DNA could be at work.

For whatever reason, the result is that human proteins resemble those expressed by a multitude of today’s viruses and other pathogens. Upon infection, these pathogens are thus able to interfere with the function of their human counterparts in a number of ways (see below).

3.5. Copy Number Variations and the Effects of Parental Age on Risk

Repeated viral insertion could well explain copy number variations, which are associated with a number of diseases, including schizophrenia [72, 73]. As their number increases, so will the number of matches to the same viral proteins, thus increasing the risk of viral interference and autoimmunity. As viral infection can be passed from parent to child via chromosomal integration, perhaps this is also why both paternal and maternal older age have been reported as risk factors in schizophrenia and other disorders [74, 75].

3.6. KEGG Pathway Analysis of Schizophrenia Susceptibility Genes

The color-coded pathways for this analysis are posted at http://www.polygenicpathways.co.uk/keggszgenes.htm. It confirmed the involvement of a number of polygenic pathways, including long-term potentiation and oxidative stress [3] growth factor/neuregulin pathways [121], neuroactive ligand pathways (dopamine/serotonin/glutamate and others) as well as dopamine metabolism pathways [9]. In the context of this review, a large number of immune-related pathways are traced out by these genes, together with many pathogen-related pathways, including toxoplasmosis, which heads the list (Table 5). The involvement of schizophrenia related genes in the life cycles of pathogens has been the subject of a previous review [22] and this relationship is supported by this analysis. Other pathogen related pathways relating to amoebiasis, Staphylococcus aureus and Helicobacter pylori infection, might indicate the involvement of other pathogens in schizophrenia, although such pathways could also be considered as generic pathways related to many pathogens.


Pathogen pathwaysViral pathwaysImmune

Toxoplasmosis16Focal adhesion20Cytokine-cytokine receptor interaction26
Chagas disease15Cell adhesion molecules (CAMs)19Jak-STAT signaling pathway16
Amoebiasis13Regulation of actin cytoskeleton17Systemic lupus erythematosus13
Leishmaniasis12Protein processing in endoplasmic reticulum13T cell receptor signaling pathway13
Viral myocarditis8Endocytosis12Phagosome12
Staphylococcus aureus infection7Phagosome12Allograft rejection11
Epithelial cell signaling in Helicobacter pylori infection6Gap junction11Hematopoietic cell lineage11
Malaria6Tight junction11Antigen processing and presentation10
Tryptophan metabolism6Adherens junction6Fc epsilon RI signaling pathway10
NOD-like receptor signaling pathway4ECM-receptor interaction6Apoptosis10
Vibrio cholerae infection4Oocyte meiosis5Graft-versus-host disease9
Bacterial invasion of epithelial cells3SNARE interactions in vesicular transport4Autoimmune thyroid disease8
E.coli infection3Chemokine signaling pathway8
RIG-I-like receptor signaling pathway3Basal transcription factors3Leukocyte transendothelial migration8
Cytosolic DNA-sensing pathway2Spliceosome2Natural killer cell mediated cytotoxicity8
Shigellosis2Aminoacyl-tRNA biosynthesis1Adipocytokine signaling pathway7
Base excision repair1Asthma7
RNA degradation1Intestinal IgA production5
Toll-like receptor signaling pathway5
Complement and coagulation cascades4
B cell receptor signaling pathway3
TGF-beta signaling pathway3
Lysosome2
Regulation of autophagy2
Fc gamma R-mediated phagocytosis1
Primary immunodeficiency1

There is no specific viral life cycle pathway within the KEGG dataset. However, viruses use adhesion molecules as receptors, endocytosis for cellular entry and the intracellular actin and tubulin networks for migration to and from the nucleus, mediated via dynein and kinesin motors. They also subjugate intracellular vesicular trafficking pathways, and are able to subvert both lysosomal and phagosomal pathways. Their exit may depend upon exocytosis, or by apoptotic or other means of killing their host cell [122]. These pathways are heavily represented within the schizophrenia gene analysis.

3.7. Mechanisms of Action

Individual proteins are homologous to multiple viral proteins, which nevertheless are specific for a spectrum of viruses, while individual viruses are homologous to a large but specific subset of human proteins.

Our proteomes therefore contain proteins with sequences exactly matching those in the current virome, and in the proteomes of bacteria and other pathogens, which are also subject to phage or viral infection. Pathogens’ proteins are therefore homologous to receptors, transporters, peptide messengers, growth factors, and other protein products of diverse gene families. Upon infection, surrogate dopamine, NMDA serotonin and other receptors, as well as transporters and enzymes are made available, which in effect may steal the ligands of their human counterparts. It is already known that the dopaminergic ligand, amantadine, binds to the influenza virus [123], which expresses proteins homologous to dopamine receptors (Table 3). When homologous to peptide ligands, viral proteins may occupy and block or perhaps stimulate their cognate receptors, or use them for entry, as is the case with the AIDS virus and the CCR5 and CXCR4 chemokine receptors [124].

This is illustrated by the Norovirus (Norwalk) which causes vomiting sickness. The virus expresses proteins homologous to monoamine and other amine oxidases as well as to a number of dopamine and monoamine transporters (Table 6). Dopamine subversion by the viral homologues would be expected to increase dopamine levels resulting in emesis, thus explaining the recurrent vomiting produced by infection.


Dopamine metabolisersAmine transportersOthers

AOC2 amine oxidases
AOC3“”
KDM1A amine oxidase demethylase
KDM1B“”
MAOA monoamine oxidase
MAOB“”
RNLS renalase amine oxidase
SMOX spermine oxidase
SPR sepiapterin reductase
Monoamine synthesis cofactor
SULT1A1 sulphotransferases
SULT1A3 monoamine metabolite sulphation
SULT1A4
SLC6A2 (Noradrenaline)
SLC6A3 (Dopamine)
SLC18A1vesicular monoamine
SLC18A2“”
SLC22A2 organic cation
SLC22A3 extraneuronal monoamine
SLC29A4 (Na+/H+)
CADPS2 amine release activator
CDCA7 cell division cycle associated 7
CDCA7L
IL4I1 cytokine
PICK1 postsynaptic scaffold

The potential interference by viruses within protein/protein networks is well illustrated by the homology of rubella proteins to DISC1 and other members of its interactome, and by the fact that many viruses have indeed been found to bind to these components (Table 4).

The homologous human proteins of the viral risk factors implicated in schizophrenia correspond to the genomic locations of 632 schizophrenia susceptibility genes (see Venn diagrams). Both negative and positive genetic association results have been reported for these many genes and it now seems plausible that, in some cases, this may be due to the presence or absence of active infection with these and other pathogens, and that DNA assays have been detecting pathogen as well as human DNA in the blood samples used for assay. There is evidently no way of discriminating viral or bacterial double-stranded DNA from human DNA.

This is not specific to schizophrenia, as the viruses implicated in Alzheimer’s disease (HSV-1, HIV-1, HHV-6 and the cytomegalovirus) [125127] are also homologous to proteins encoded by Alzheimer’s disease susceptibility genes see http://www.polygenicpathways.co.uk/blasts.htm [128].

It seems that a viable interpretation, given the same phenomenon in these diseases, is that these genes are susceptibility genes precisely because they encode for proteins with homology to the viral risk factors. Infection and genetics therefore appear to be interdependent. The pathogens may promote disease if the human genes encode for homologous products, and the genes promote disease if the homologous pathogen is encountered. Such interdependence likely explains the heterogeneous data in both gene and risk factor association studies.

Other pathogens, including Borrelia Burgdorferri and T. Gondii have also been implicated in schizophrenia. These too express many homologous proteins to both viral and human proteomes. These parasites tend to be associated with schizophrenia in adulthood, while viral infections are predominantly prenatal risk factors. These may have primed the antibody network to respond to homologous antigens expressed by Borrelia or T. Gondii, suggesting that detection and elimination of these pathogens may be of therapeutic benefit in adult life.

Schizophrenia is a neurodevelopmental disorder [129, 130] and, as the risk-promoting effects of viruses are related to maternal infection, it is possible that knockdown or interference of foetal proteins by viral-induced antibodies targeting their human counterparts may contribute to the neurodevelopmental disturbances observed in schizophrenia. Indeed DISC1, neuregulin, ERBB4, FEZ1 or COMT knockout mice display many of the pathological and behavioural symptoms associated with schizophrenia [131135]. Viral interference with these same proteins might be expected to promote the same effects, but on a massive scale, targeting many relevant proteins at once. It is also possible that such autoantibodies play a role in the comorbid conditions associated with schizophrenia, for example autoimmune disease such as Thyrotoxicosis, celiac disease, acquired haemolytic anaemia, interstitial cystitis, or Sjogren's syndrome [136].

Autoantibodies to several proteins have been reported in schizophrenia (muscarinic, nicotinic, dopaminergic and NMDA receptors, inter alia, (Table 2) and all are homologous to proteins expressed by the risk factors in schizophrenia. The effects of antibody knockdown have not been analysed for any schizophrenia related proteins, but have been reported for the microtubule-related protein tau, in relation to Alzheimer’s disease. In mice, tau immunisation produces tau hyperphosphorylation, neurofibrillary tangles and axonal damage as seen in the human condition [137]. Tau (MAPT) is homologous to Herpes simplex (HSV-1) and a number of other pathogens. Such effects are relevant to the autoantigens observed in schizophrenia.

Schizophrenia is also a degenerative disease in adolescence or adulthood, characterised by oligodendrocyte cell loss, impaired synaptic connectivity and pyramidal cell dendrite shrinkage [41, 138140], In the light of the above homologies it seems likely that such degenerative changes may relate to autoimmune-related attack of these diverse compartments. Indeed there is evidence for microglial activation in the schizophrenic brain [141] and several studies have reported changes in the cytokine profile in the brain, CSF or peripheral immune compartments [24, 142146].

3.8. Clinical Implications in Schizophrenia and Other Conditions

These data suggest that susceptibility gene products are the vehicles enabling the risk-promoting effects of pathogenic risk factors, via the interactions described above, and that the two are indispensable for the genesis of schizophrenia. Pathogen detection and elimination or vaccination, particularly prior to pregnancy might be expected to reduce the incidence of schizophrenia and also to be of clinical benefit in adulthood. Interestingly, vitamin D is able to stunt the growth of T. Gondii [147] and low levels of this vitamin, both prenatally and in adulthood, have been associated with schizophrenia risk, although abnormally high levels are also a risk factor [148]. Pharmaceutical effort in this direction may also vastly improve the armoury and safety of drugs against parasites such as T. Gondii and Borrelia.

Autoimmunity, involving several key schizophrenia-related proteins may well be a consequence of pathogen infection, and related to viral/human protein homology. Antigen and antibody removal by immunoadsorption techniques might therefore also be if clinical benefit.

This scenario suggests a novel and probably common class of “pathogenetic” autoimmune disease caused by pathogens but dependent on our genes. Indeed, the same phenomenon has been observed in Alzheimer’s disease where the risk factor herpes simplex expresses proteins containing peptide matches to the products of multiple susceptibility genes [128]. Work from Kanduc’s laboratory has also shown that 30 viral proteomes, including many nonretroviruses, contain multiple pentapeptide matches to many human proteins [149]. This is corroborated by data posted at http://www.polygenicpathways.co.uk/blasts.htm which shows, inter alia, that Bornavirus proteins, a virus implicated in Bipolar disorder [150], display this type of homology in relation to Bipolar disorder susceptibility gene products, that the coronavirus implicated in Parkinson’s disease [151] expresses proteins homologous to the PARK7 gene product and to dopaminergic and oxidative stress-related proteins, and that multiple sclerosis autoantigens are homologous to the products of the Epstein-Barr virus which has been implicated in this disorder [152]. Our genomes and polymorphisms determine which vatches we possess, which pathogens match these sequences and which pathogen-related disorder we might develop. Environmental variables, and vaccination, determine which pathogens we encounter and our immune system (HLA-antigens and immune background determined soon after birth) may determine how we deal with these pathogens. With the power of current day bioinformatics, it should be possible to rapidly identify all vatches in the human proteome and to pair them with the various pathogenic species and human diseases. This would greatly aid our understanding of the implication of pathogens in disease and may lead to radically new therapies and prevention strategies in many disorders.

References

  1. T. J. Crow, “How and why genetic linkage has not solved the problem of psychosis: review and hypothesis,” American Journal of Psychiatry, vol. 164, no. 1, pp. 13–21, 2007. View at: Publisher Site | Google Scholar
  2. M. J. Owen, N. Craddock, and M. C. O'Donovan, “Schizophrenia: genes at last?” Trends in Genetics, vol. 21, no. 9, pp. 518–525, 2005. View at: Publisher Site | Google Scholar
  3. C. J. Carter, “Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability,” Schizophrenia Research, vol. 86, no. 1–3, pp. 1–14, 2006. View at: Publisher Site | Google Scholar
  4. C. J. Carter, “eIF2B and oligodendrocyte survival: where nature and nurture meet in bipolar disorder and schizophrenia?” Schizophrenia Bulletin, vol. 33, no. 6, pp. 1343–1353, 2007. View at: Publisher Site | Google Scholar
  5. A. K. Khler, S. Djurovic, L. M. Rimol et al., “Candidate gene analysis of the human natural killer-1 carbohydrate pathway and perineuronal nets in schizophrenia: B3GAT2 Is associated with disease risk and cortical surface area,” Biological Psychiatry, vol. 69, no. 1, pp. 90–96, 2011. View at: Publisher Site | Google Scholar
  6. P. Jia, L. Wang, H. Y. Meltzer, and Z. Zhao, “Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data,” Schizophrenia Research, vol. 122, no. 1–3, pp. 38–42, 2010. View at: Publisher Site | Google Scholar
  7. C. O'Dushlaine, E. Kenny, E. Heron et al., “Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility,” Molecular Psychiatry, vol. 16, no. 3, pp. 286–292, 2010. View at: Publisher Site | Google Scholar
  8. K. K. Nicodemus, A. J. Law, E. Radulescu et al., “Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls,” Archives of General Psychiatry, vol. 67, no. 10, pp. 991–1001, 2010. View at: Google Scholar
  9. M. E. Talkowski, G. Kirov, M. Bamne et al., “A network of dopaminergic gene variations implicated as risk factors for schizophrenia,” Human Molecular Genetics, vol. 17, no. 5, pp. 747–758, 2008. View at: Publisher Site | Google Scholar
  10. K. K. Nicodemus, J. H. Callicott, R. G. Higier et al., “Evidence of statistical epistasis between DISC1, CIT and NDEL1 impacting risk for schizophrenia: biological validation with functional neuroimaging,” Human Genetics, vol. 127, no. 4, pp. 441–452, 2010. View at: Publisher Site | Google Scholar
  11. A. S. Brown, P. Cohen, S. Greenwald, and E. Susser, “Nonaffective psychosis after prenatal exposure to rubella,” American Journal of Psychiatry, vol. 157, no. 3, pp. 438–443, 2000. View at: Publisher Site | Google Scholar
  12. W. Adams, R. E. Kendell, E. H. Hare, and P. Munk-Jorgensen, “Epidemiological evidence that maternal influenza contributes to the aetiology of schizophrenia. An analysis of Scottish, English, and Danish data,” British Journal of Psychiatry, vol. 163, pp. 522–534, 1993. View at: Google Scholar
  13. A. S. Brown, M. D. Begg, S. Gravenstein et al., “Serologic evidence of prenatal influenza in the etiology of schizophrenia,” Archives of General Psychiatry, vol. 61, no. 8, pp. 774–780, 2004. View at: Publisher Site | Google Scholar
  14. E. F. Torrey, R. Rawlings, and I. N. Waldman, “Schizophrenic births and viral diseases in two states,” Schizophrenia Research, vol. 1, no. 1, pp. 73–77, 1988. View at: Publisher Site | Google Scholar
  15. P. B. Mortensen, C. B. Pedersen, D. M. Hougaard et al., “A Danish National Birth Cohort study of maternal HSV-2 antibodies as a risk factor for schizophrenia in their offspring,” Schizophrenia Research, no. 1–3, pp. 257–263, 2010. View at: Publisher Site | Google Scholar
  16. G. Stober, E. Franzek, and H. Beckmann, “Pregnancy infections in mothers of chronic schizophrenic patients. The significance of differential nosology [Schwangerschaftsinfektionen bei Muttern von chronisch Schizophrenen. Die Bedeutung einer differenzierten Nosologie],” Nervenarzt, vol. 65, no. 3, pp. 175–182, 1994. View at: Google Scholar
  17. J. Suvisaari, J. Haukka, A. Tanskanen, T. Hovi, and J. Lönnqvist, “Association between prenatal exposure to poliovirus infection and adult schizophrenia,” American Journal of Psychiatry, vol. 156, no. 7, pp. 1100–1102, 1999. View at: Google Scholar
  18. P. Rantakallio, P. Jones, J. Moring, and L. von Wendt, “Association between central nervous system infections during childhood and adult onset schizophrenia and other psychoses: a 28-year follow-up,” International Journal of Epidemiology, vol. 26, no. 4, pp. 837–843, 1997. View at: Publisher Site | Google Scholar
  19. R. H. Yolken and E. F. Torrey, “Are some cases of psychosis caused by microbial agents? A review of the evidence,” Molecular Psychiatry, vol. 13, no. 5, pp. 470–479, 2008. View at: Publisher Site | Google Scholar
  20. M. Fritzsche, “Seasonal correlation of sporadic schizophrenia to Ixodes ticks and Lyme borreliosis,” International Journal of Health Geographics, vol. 1, article 2, 2002. View at: Publisher Site | Google Scholar
  21. H. Karlsson, S. Bachmann, J. Schröder, J. McArthur, E. F. Torrey, and R. H. Yolken, “Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 8, pp. 4634–4639, 2001. View at: Publisher Site | Google Scholar
  22. C. J. Carter, “Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: cytomegalovirus, influenza, herpes simplex, rubella, and Toxoplasma gondii,” Schizophrenia Bulletin, vol. 35, no. 6, pp. 1163–1182, 2009. View at: Google Scholar
  23. J. Sun, P. Jia, A. H. Fanous et al., “Schizophrenia gene networks and pathways and their applications for novel candidate gene selection,” PLoS One, vol. 5, no. 6, Article ID e11351, 2010. View at: Publisher Site | Google Scholar
  24. N. Müller, “The role of the cytokine network in the CNS and psychic disorders,” Nervenarzt, vol. 68, no. 1, pp. 11–20, 1997. View at: Publisher Site | Google Scholar
  25. M. Rothermundt, V. Arolt, and T. A. Bayer, “Review of immunological and immunopathological findings in schizophrenia,” Brain, Behavior, and Immunity, vol. 15, no. 4, pp. 319–339, 2001. View at: Publisher Site | Google Scholar
  26. S. Theodoropoulou, G. Spanakos, C. N. Baxevanis et al., “Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients,” Schizophrenia Research, vol. 47, no. 1, pp. 13–25, 2001. View at: Publisher Site | Google Scholar
  27. K. F. Tanaka, F. Shintani, Y. Fujii, G. Yagi, and M. Asai, “Serum interleukin-18 levels are elevated in schizophrenia,” Psychiatry Research, vol. 96, no. 1, pp. 75–80, 2000. View at: Publisher Site | Google Scholar
  28. M. C. O'Donnell, S. V. Catts, P. B. Ward et al., “Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder,” Psychiatry Research, vol. 65, no. 3, pp. 171–178, 1996. View at: Publisher Site | Google Scholar
  29. R. Ganguli, B. S. Rabin, R. H. Kelly, M. Lyte, and U. Ragu, “Clinical and laboratory evidence of autoimmunity in acute schizophrenia,” Annals of the New York Academy of Sciences, vol. 496, pp. 676–685, 1987. View at: Google Scholar
  30. M. Makinodan, K. Tatsumi, T. Manabe et al., “Maternal immune activation in mice delays myelination and axonal development in the hippocampus of the offspring,” Journal of Neuroscience Research, vol. 86, no. 10, pp. 2190–2200, 2008. View at: Publisher Site | Google Scholar
  31. S. F. Altschul, T. L. Madden, A. A. Schäffer et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Research, vol. 25, no. 17, pp. 3389–3402, 1997. View at: Publisher Site | Google Scholar
  32. J. E. Larsen, O. Lund, and M. Nielsen, “Improved method for predicting linear B-cell epitopes,” Immunome Research, vol. 2, p. 2, 2006. View at: Google Scholar
  33. S. Goto, H. Bono, H. Ogata et al., “Organizing and computing metabolic pathway data in terms of binary relations,” Pacific Symposium on Biocomputing, pp. 175–186, 1997. View at: Google Scholar
  34. M. Pirooznia, V. Nagarajan, and Y. Deng, “GeneVenn—a web application for comparing gene lists using Venn diagrams,” Bioinformation, vol. 1, pp. 420–422, 2007. View at: Google Scholar
  35. D. Kanduc, “Describing the hexapeptide identity platform between the influenza A H5N1 and Homo sapiens proteomes,” Biologics, vol. 4, pp. 245–261, 2010. View at: Google Scholar
  36. S. Himelhoch, J. F. McCarthy, D. Ganoczy et al., “Understanding associations between serious mental illness and hepatitis C virus among veterans: a national multivariate analysis,” Psychosomatics, vol. 50, no. 1, pp. 30–37, 2009. View at: Publisher Site | Google Scholar
  37. J. G. Baillargeon, D. P. Paar, H. Wu et al., “Psychiatric disorders, HIV infection and HIV/hepatitis co-infection in the correctional setting,” AIDS Care, vol. 20, no. 1, pp. 124–129, 2008. View at: Publisher Site | Google Scholar
  38. C. P. Carney, L. Jones, and R. F. Woolson, “Medical comorbidity in women and men with schizophrenia: a population-based controlled study,” Journal of General Internal Medicine, vol. 21, no. 11, pp. 1133–1137, 2006. View at: Publisher Site | Google Scholar
  39. F. Cournos, K. McKinnon, and G. Sullivan, “Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus,” Journal of Clinical Psychiatry, vol. 66, no. 6, pp. 27–33, 2005. View at: Google Scholar
  40. M. S. van der Knaap, J. C. Pronk, and G. C. Scheper, “Vanishing white matter disease,” The Lancet Neurology, vol. 5, no. 5, pp. 413–423, 2006. View at: Publisher Site | Google Scholar
  41. N. Uranova, D. Orlovskaya, O. Vikhreva et al., “Electron microscopy of oligodendroglia in severe mental illness,” Brain Research Bulletin, vol. 55, no. 5, pp. 597–610, 2001. View at: Publisher Site | Google Scholar
  42. V. Vostrikov, D. Orlovskaya, and N. Uranova, “Deficit of pericapillary oligodendrocytes in the prefrontal cortex in schizophrenia,” World Journal of Biological Psychiatry, vol. 9, no. 1, pp. 34–42, 2008. View at: Publisher Site | Google Scholar
  43. V. M. Vostrikov, “Decreased numerical density of pericapillary oligodendrocytes in the cortex in schizophrenia,” Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova, vol. 107, no. 12, pp. 58–65, 2007. View at: Google Scholar
  44. Y. Hakak, J. R. Walker, C. Li et al., “Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 8, pp. 4746–4751, 2001. View at: Publisher Site | Google Scholar
  45. D. R. Friedlander, P. Milev, L. Karthikeyan, R. K. Margolis, R. U. Margolis, and M. Grumet, “The neuronal chondroitin sulfate proteoglycan neurocan binds to the neural cell adhesion molecules Ng-CAM/L1/NILE and N-CAM, and inhibits neuronal adhesion and neurite outgrowth,” Journal of Cell Biology, vol. 125, no. 3, pp. 669–680, 1994. View at: Google Scholar
  46. A. Sandvig, M. Berry, L. B. Barrett, A. Butt, and A. Logan, “Myelin-, reactive glia-, and scar-derived CNS axon growth inhibitors: expression, receptor signaling, and correlation with axon regeneration,” Glia, vol. 46, no. 3, pp. 225–251, 2004. View at: Publisher Site | Google Scholar
  47. Z. J. Chen, Y. Ughrin, and J. M. Levine, “Inhibition of axon growth by oligodendrocyte precursor cells,” Molecular and Cellular Neuroscience, vol. 20, no. 1, pp. 125–139, 2002. View at: Publisher Site | Google Scholar
  48. H. P. Li, A. Oohira, M. Ogawa, K. Kawamura, and H. Kawano, “Aberrant trajectory of thalamocortical axons associated with abnormal localization of neurocan immunoreactivity in the cerebral neocortex of reeler mutant mice,” European Journal of Neuroscience, vol. 22, no. 11, pp. 2689–2696, 2005. View at: Publisher Site | Google Scholar
  49. K. Verhoeven, P. de Jonghe, T. van de Putte et al., “Slowed conduction and thin myelination of peripheral nerves associated with mutant rho Guanine-nucleotide exchange factor 10,” American Journal of Human Genetics, vol. 73, no. 4, pp. 926–932, 2003. View at: Publisher Site | Google Scholar
  50. D. Ben-Shachar and R. Karry, “Neuroanatomical pattern of mithochondrial complex I pathology varies between schizoprenia, bipolar disorder and major depression,” PLoS One, vol. 3, no. 11, Article ID e3676, 2008. View at: Publisher Site | Google Scholar
  51. E. Y. Yuen and Z. Yan, “Dopamine D4 receptors regulate AMPA receptor trafficking and glutamatergic transmission in GABAergic interneurons of prefrontal cortex,” Journal of Neuroscience, vol. 29, no. 2, pp. 550–562, 2009. View at: Publisher Site | Google Scholar
  52. K. Fukunaga and Y. Takeuchi, “Novel intracellular signal transduction of dopamine D2 receptor in schizophrenia,” Tanpakushitsu Kakusan Koso, vol. 51, no. 11, pp. 1602–1608, 2006. View at: Google Scholar
  53. T. Miyakawa, L. M. Leiter, D. J. Gerber et al., “Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8987–8992, 2003. View at: Publisher Site | Google Scholar
  54. J. P. B. Viola and A. Rao, “Role of the cyclosporin-sensitive transcription factor NFAT1 in the allergic response,” Memorias do Instituto Oswaldo Cruz, vol. 92, supplement 2, pp. 147–155, 1997. View at: Google Scholar
  55. A. Andrieux, P. A. Salin, M. Vernet et al., “The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders,” Genes and Development, vol. 16, no. 18, pp. 2350–2364, 2002. View at: Publisher Site | Google Scholar
  56. A. Andrieux, P. A. Salin, and D. Job, “A role for the cytoskeleton in mental diseases? [Un rôle pour les microtubules dans les pathologies psychiatriques?],” Pathologie Biologie, vol. 52, no. 2, pp. 89–92, 2004. View at: Publisher Site | Google Scholar
  57. A. Arcangeli, B. Rosati, A. Cherubini et al., “HERG- and IRK-like inward rectifier currents are sequentially expressed during neuronal development of neural crest cells and their derivatives,” European Journal of Neuroscience, vol. 9, no. 12, pp. 2596–2604, 1997. View at: Publisher Site | Google Scholar
  58. G. A. M. Smith, H. W. Tsui, E. W. Newell et al., “Functional up-regulation of HERG K channels in neoplastic hematopoietic cells,” Journal of Biological Chemistry, vol. 277, no. 21, pp. 18528–18534, 2002. View at: Publisher Site | Google Scholar
  59. J. Gommeaux, C. Grégoire, P. Nguessan et al., “Thymus-specific serine protease regulates positive selection of a subset of CD4+ thymocytes,” European Journal of Immunology, vol. 39, no. 4, pp. 956–964, 2009. View at: Publisher Site | Google Scholar
  60. A. Buonanno, O. B. Kwon, L. Yan et al., “Neuregulins and neuronal plasticity: possible relevance in schizophrenia,” Novartis Foundation Symposium, vol. 289, pp. 165–177, 2008. View at: Google Scholar
  61. P. Seeman, “Glutamate and dopamine components in schizophrenia,” Journal of Psychiatry and Neuroscience, vol. 34, no. 2, pp. 143–149, 2009. View at: Google Scholar
  62. N. A. Uranova, V. M. Vostrikov, D. D. Orlovskaya, and V. I. Rachmanova, “Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium,” Schizophrenia Research, vol. 67, no. 2-3, pp. 269–275, 2004. View at: Publisher Site | Google Scholar
  63. C. Winter, T. J. Reutiman, T. D. Folsom et al., “Dopamine and serotonin levels following prenatal viral infection in mouse-Implications for psychiatric disorders such as schizophrenia and autism,” European Neuropsychopharmacology, vol. 18, no. 10, pp. 712–716, 2008. View at: Publisher Site | Google Scholar
  64. J. K. Millar, J. C. Wilson-Annan, S. Anderson et al., “Disruption of two novel genes by a translocation co-segregating with schizophrenia,” Human Molecular Genetics, vol. 9, no. 9, pp. 1415–1423, 2000. View at: Google Scholar
  65. L. M. Camargo, Q. Wang, and N. J. Brandon, “What can we learn from the disrupted in schizophrenia 1 interactome: lessons for target identification and disease biology?” Novartis Foundation Symposium, vol. 289, pp. 208–216, 2008. View at: Google Scholar
  66. W. Hennah and D. Porteous, “The DISC1 pathway modulates expression of neurodevelopmental, synaptogenic and sensory perception genes,” PLoS One, vol. 4, no. 3, Article ID e4906, 2009. View at: Publisher Site | Google Scholar
  67. S. Rossner, U. Ueberham, R. Schlichs, J. R. Perez-Polo, and V. Bigl, “Neurotrophin binding to the p75 neurotrophin receptor is necessary but not sufficient to mediate NGF-effects on APP secretion in PC-12 cells,” Journal of Neural Transmission, Supplement, no. 54, pp. 279–285, 1998. View at: Google Scholar
  68. A. Katzourakis and R. J. Gifford, “Endogenous viral elements in animal genomes,” PLoS Genetics, vol. 6, no. 11, Article ID e1001191, 2010. View at: Publisher Site | Google Scholar
  69. M. B. Geuking, J. Weber, M. Dewannieux et al., “Recombination of retrotransposon and exogenous RNA virus results in nonretroviral cDNA integration,” Science, vol. 323, no. 5912, pp. 393–396, 2009. View at: Publisher Site | Google Scholar
  70. K. Tanaka-Taya, J. Sashihara, H. Kurahashi et al., “Human herpesvirus 6 (HHV-6) is transmitted from parent to child in an integrated form and characterization of cases with chromosomally integrated HHV-6 DNA,” Journal of Medical Virology, vol. 73, no. 3, pp. 465–473, 2004. View at: Publisher Site | Google Scholar
  71. K. Khodosevich, Y. Lebedev, and E. Sverdlov, “Endogenous retroviruses and human evolution,” Comparative and Functional Genomics, vol. 3, no. 6, pp. 494–498, 2002. View at: Publisher Site | Google Scholar
  72. A. S. Brown, “Prenatal infection as a risk factor for schizophrenia,” Schizophrenia Bulletin, vol. 32, no. 2, pp. 200–202, 2006. View at: Publisher Site | Google Scholar
  73. K. Ozawa, K. Hashimoto, T. Kishimoto, E. Shimizu, H. Ishikura, and M. Iyo, “Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia,” Biological Psychiatry, vol. 59, no. 6, pp. 546–554, 2006. View at: Publisher Site | Google Scholar
  74. H. G. Kinnell, “Parental age in schizophrenia,” British Journal of Psychiatry, vol. 142, p. 204, 1983. View at: Google Scholar
  75. J. Lopez-Castroman, D. D. Gómez, J. J. C. Belloso et al., “Differences in maternal and paternal age between Schizophrenia and other psychiatric disorders,” Schizophrenia Research, vol. 116, no. 2-3, pp. 184–190, 2010. View at: Publisher Site | Google Scholar
  76. A. S. Brown, P. Cohen, S. Greenwald, and E. Susser, “Nonaffective psychosis after prenatal exposure to rubella,” American Journal of Psychiatry, vol. 157, no. 3, pp. 438–443, 2000. View at: Publisher Site | Google Scholar
  77. C. Dalman, P. Allebeck, D. Gunnell et al., “Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects,” American Journal of Psychiatry, vol. 165, no. 1, pp. 59–65, 2008. View at: Publisher Site | Google Scholar
  78. K. M. Prasad, M. N. Bamne, B. H. Shirts et al., “Grey matter changes associated with host genetic variation and exposure to Herpes Simplex Virus 1 (HSV1) in first episode schizophrenia,” Schizophrenia Research, vol. 118, no. 1–3, pp. 232–239, 2010. View at: Publisher Site | Google Scholar
  79. D. W. Niebuhr, A. M. Millikan, R. Yolken, Y. Li, and N. S. Weber, “Results from a hypothesis generating case-control study: herpes family viruses and schizophrenia among military personnel,” Schizophrenia Bulletin, vol. 34, no. 6, pp. 1182–1188, 2008. View at: Publisher Site | Google Scholar
  80. A. L. Abrahao, R. Focaccia, and W. F. Gattaz, “Childhood meningitis increases the risk for adult schizophrenia,” World Journal of Biological Psychiatry, vol. 6, no. 2, pp. 44–48, 2005. View at: Publisher Site | Google Scholar
  81. H. Terayama, Y. Nishino, M. Kishi, K. Ikuta, M. Itoh, and K. Iwahashi, “Detection of anti-Borna Disease Virus (BDV) antibodies from patients with schizophrenia and mood disorders in Japan,” Psychiatry Research, vol. 120, no. 2, pp. 201–206, 2003. View at: Publisher Site | Google Scholar
  82. S. L. Buka, T. D. Cannon, E. F. Torrey, and R. H. Yolken, “Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring,” Biological Psychiatry, vol. 63, no. 8, pp. 809–815, 2008. View at: Publisher Site | Google Scholar
  83. E. G. Severance, F. B. Dickerson, R. P. Viscidi et al., “Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms,” Schizophrenia Bulletin, vol. 37, no. 1, pp. 101–107, 2011. View at: Publisher Site | Google Scholar
  84. L. M. Ellman, R. H. Yolken, S. L. Buka, E. F. Torrey, and T. D. Cannon, “Cognitive functioning prior to the onset of psychosis: the role of fetal exposure to serologically determined influenza infection,” Biological Psychiatry, vol. 65, no. 12, pp. 1040–1047, 2009. View at: Publisher Site | Google Scholar
  85. Y. Yao, J. Schröder, C. Nellåker et al., “Elevated levels of human endogenous retrovirus-W transcripts in blood cells from patients with first episode schizophrenia,” Genes, Brain and Behavior, vol. 7, no. 1, pp. 103–112, 2008. View at: Publisher Site | Google Scholar
  86. A. S. Brown, C. A. Schaefer, C. P. Quesenberry, L. Liu, V. P. Babulas, and E. S. Susser, “Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring,” American Journal of Psychiatry, vol. 162, no. 4, pp. 767–773, 2005. View at: Publisher Site | Google Scholar
  87. F. Dickerson, C. Stallings, A. Origoni, C. Copp, S. Khushalani, and R. Yolken, “Antibodies to measles in individuals with recent onset psychosis,” Schizophrenia Research, vol. 119, no. 1–3, pp. 89–94, 2010. View at: Publisher Site | Google Scholar
  88. G. P. Amminger, P. D. McGorry, G. E. Berger et al., “Antibodies to infectious agents in individuals at ultra-high risk for psychosis,” Biological Psychiatry, vol. 61, no. 10, pp. 1215–1217, 2007. View at: Publisher Site | Google Scholar
  89. M. J. Chandley, M. N. Miller, C. N. Kwasigroch, T. D. Wilson, and B. E. Miller, “Increased antibodies for the α7 subunit of the nicotinic receptor in schizophrenia,” Schizophrenia Research, vol. 109, no. 1–3, pp. 98–101, 2009. View at: Publisher Site | Google Scholar
  90. T. Borda, R. Gomez, M. I. Berría, and L. Sterin-Borda, “Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera,” Glia, vol. 45, no. 2, pp. 144–154, 2004. View at: Publisher Site | Google Scholar
  91. Y. Suzuki, T. Kurita, K. Sakurai, Y. Takeda, and T. Koyama, “Case report of anti-NMDA receptor encephalitis suspected of schizophrenia,” Seishin Shinkeigaku Zasshi, vol. 111, no. 12, pp. 1479–1484, 2009. View at: Google Scholar
  92. I. V. Shcherbakova, T. M. Siryachenko, N. A. Mazaeva, V. G. Kaleda, S. A. Krasnolobova, and T. P. Klyushnik, “Leukocyte elastase and autoantibodies to nerve growth factor in the acute phase of schizophrenia and their relationship to symptomatology,” World Journal of Biological Psychiatry, vol. 5, no. 3, pp. 143–148, 2004. View at: Publisher Site | Google Scholar
  93. S. Tanaka, H. Matsunaga, M. Kimura et al., “Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders,” Journal of Neuroimmunology, vol. 141, no. 1-2, pp. 155–164, 2003. View at: Publisher Site | Google Scholar
  94. X. F. Wang, D. Wang, W. Zhu, K. K. Delrahim, D. Dolnak, and M. H. Rapaport, “Studies characterizing 60 kDa autoantibodies in subjects with schizophrenia,” Biological Psychiatry, vol. 53, no. 5, pp. 361–375, 2003. View at: Publisher Site | Google Scholar
  95. J. J. Kim, S. J. Lee, K. Y. Toh, C. U. Lee, C. Lee, and I. H. Paik, “Identification of antibodies to heat shock proteins 90 kDa and 70 kDa in patients with schizophrenia,” Schizophrenia Research, vol. 52, no. 1-2, pp. 127–135, 2001. View at: Publisher Site | Google Scholar
  96. A. B. Poletaev, S. G. Morozov, B. B. Gnedenko, V. M. Zlunikin, and D. A. Korzhenevskey, “Serum anti-S100b, anti-GFAP and anti-NGF autoantibodies of IgG class in healthy persons and patients with mental and neurological disorders,” Autoimmunity, vol. 32, no. 1, pp. 33–38, 2000. View at: Google Scholar
  97. A. Chatr-Aryamontri, A. Ceol, D. Peluso et al., “VirusMINT: a viral protein interaction database,” Nucleic Acids Research, vol. 37, no. 1, pp. D669–D673, 2009. View at: Publisher Site | Google Scholar
  98. C. J. Carter, “Herpes simplex: host viral protein interactions,” WikiGenes, 2010. View at: Google Scholar
  99. S. Lan, H. Wang, H. Jiang et al., “Direct interaction between α-actinin and hepatitis C virus NS5B,” FEBS Letters, vol. 554, no. 3, pp. 289–294, 2003. View at: Publisher Site | Google Scholar
  100. E. Forgacs, S. K. Gupta, J. A. Kerry, and O. J. Semmes, “The bZIP transcription factor ATFx binds human T-cell leukemia virus type 1 (HTLV-1) tax and represses HTLV-1 long terminal repeat-mediated transcription,” Journal of Virology, vol. 79, no. 11, pp. 6932–6939, 2005. View at: Publisher Site | Google Scholar
  101. S. V. Indran, M. E. Ballestas, and W. J. Britt, “Bicaudal D1-dependent trafficking of human cytomegalovirus tegument protein pp150 in virus-infected cells,” Journal of Virology, vol. 84, no. 7, pp. 3162–3177, 2010. View at: Publisher Site | Google Scholar
  102. Y. P. Huang, J. Cheng, S. L. Zhang et al., “Screening of hepatocyte proteins binding to F protein of hepatitis C virus by yeast two-hybrid system,” World Journal of Gastroenterology, vol. 11, no. 36, pp. 5659–5665, 2005. View at: Google Scholar
  103. K. Radtke, D. Kieneke, A. Wolfstein et al., “Plus- and minus-end directed microtubule motors bind simultaneously to herpes simplex virus capsids using different inner tegument structures,” PLoS Pathogens, vol. 6, no. 7, Article ID e1000991, 2010. View at: Publisher Site | Google Scholar
  104. K. H. Bremner, J. Scherer, J. Yi, M. Vershinin, S. P. Gross, and R. B. Vallee, “Adenovirus transport via direct interaction of cytoplasmic dynein with the viral capsid hexon subunit,” Cell Host and Microbe, vol. 6, no. 6, pp. 523–535, 2010. View at: Publisher Site | Google Scholar
  105. H. Si, S. C. Verma, M. A. Lampson, Q. Cai, and E. S. Robertson, “Kaposi's sarcoma-associated herpesvirus-encoded LANA can interact with the nuclear mitotic apparatus protein to regulate genome maintenance and segregation,” Journal of Virology, vol. 82, no. 13, pp. 6734–6746, 2008. View at: Publisher Site | Google Scholar
  106. H. N. Ramanathan, D. H. Chung, S. J. Plane et al., “Dynein-dependent transport of the Hantaan virus nucleocapsid protein to the endoplasmic reticulum-Golgi intermediate compartment,” Journal of Virology, vol. 81, no. 16, pp. 8634–8647, 2007. View at: Publisher Site | Google Scholar
  107. B. Schramm, C. A. M. de Haan, J. Young et al., “Vaccinia-virus-induced cellular contractility facilitates the subcellular localization of the viral replication sites,” Traffic, vol. 7, no. 10, pp. 1352–1367, 2006. View at: Publisher Site | Google Scholar
  108. I. J. Dorweiler, S. J. Ruone, H. Wang, R. W. Burry, and L. M. Mansky, “Role of the human T-cell leukemia virus type 1 PTAP motif in Gag targeting and particle release,” Journal of Virology, vol. 80, no. 7, pp. 3634–3643, 2006. View at: Publisher Site | Google Scholar
  109. K. Kobayashi, T. Sueyoshi, K. Inoue, R. Moore, and M. Negishi, “Cytoplasmic accumulation of the nuclear receptor CAR by a tetratricopeptide repeat protein in HepG2 cells,” Molecular Pharmacology, vol. 64, no. 5, pp. 1069–1075, 2003. View at: Publisher Site | Google Scholar
  110. K. H. Bremner, J. Scherer, J. Yi, M. Vershinin, S. P. Gross, and R. B. Vallee, “Adenovirus transport via direct interaction of cytoplasmic dynein with the viral capsid hexon subunit,” Cell Host and Microbe, vol. 6, no. 6, pp. 523–535, 2010. View at: Publisher Site | Google Scholar
  111. E. Johannsen, M. Luftig, M. R. Chase et al., “Proteins of purified Epstein-Barr virus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 46, pp. 16286–16291, 2004. View at: Publisher Site | Google Scholar
  112. A. J. Collier, J. Gallego, R. Klinck et al., “A conserved RNA structure within the HCV IRES eIF3-binding site,” Nature Structural Biology, vol. 9, no. 5, pp. 375–380, 2002. View at: Publisher Site | Google Scholar
  113. H. Sawa, T. Suzuki, Y. Orba, Y. Sunden, and K. Nagashima, “Recent research on the JC virus,” Brain and Nerve, vol. 59, no. 2, pp. 101–108, 2007. View at: Google Scholar
  114. R. M. Vos, J. Altreuter, E. A. White, and P. M. Howley, “The ubiquitin-specific peptidase USP15 regulates human papillomavirus type 16 E6 protein stability,” Journal of Virology, vol. 83, no. 17, pp. 8885–8892, 2009. View at: Publisher Site | Google Scholar
  115. R. König, Y. Zhou, D. Elleder et al., “Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication,” Cell, vol. 135, no. 1, pp. 49–60, 2008. View at: Publisher Site | Google Scholar
  116. A. A. Kondratova, N. Neznanov, R. V. Kondratov, and A. V. Gudkov, “Poliovirus protein 3A binds and inactivates LIS1, causing block of membrane protein trafficking and deregulation of cell division,” Cell Cycle, vol. 4, no. 10, pp. 1403–1410, 2005. View at: Google Scholar
  117. N. Epie, T. Ammosova, T. Sapir et al., “HIV-1 Tat interacts with LIS1 protein,” Retrovirology, vol. 2, 2005. View at: Publisher Site | Google Scholar
  118. Y. Verdier and B. Penke, “Binding sites of amyloid β-peptide in cell plasma membrane and implications for Alzheimer's disease,” Current Protein and Peptide Science, vol. 5, no. 1, pp. 19–31, 2004. View at: Publisher Site | Google Scholar
  119. I. Bossis, R. B. S. Roden, R. Gambhira et al., “Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection,” Journal of Virology, vol. 79, no. 11, pp. 6723–6731, 2005. View at: Publisher Site | Google Scholar
  120. C. R. Brunetti, K. S. Dingwell, C. Wale, F. L. Graham, and D. C. Johnson, “Herpes simplex virus gD and virions accumulate in endosomes by mannose 6-phosphate-dependent and -independent mechanisms,” Journal of Virology, vol. 72, no. 4, pp. 3330–3339, 1998. View at: Google Scholar
  121. D. T. Balu and J. T. Coyle, “Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia,” Neuroscience and Biobehavioral Reviews, vol. 35, no. 3, pp. 848–870, 2011. View at: Publisher Site | Google Scholar
  122. S. J. Flint, L. W. Enquist, V. R. Racaniello, and A. M. Skalka, Principles of Virology, ASM Press, Herndon, Va, USA, 2008.
  123. M. R. Rosenberg and M. G. Casarotto, “Coexistence of two adamantane binding sites in the influenza A M2 ion channel,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 31, pp. 13866–13871, 2010. View at: Publisher Site | Google Scholar
  124. J. Toma, J. M. Whitcomb, C. J. Petropoulos, and W. Huang, “Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors,” AIDS, vol. 24, no. 14, pp. 2181–2186, 2010. View at: Publisher Site | Google Scholar
  125. C. J. Carter, “Interactions between the products of the Herpes simplex genome and Alzheimer's disease susceptibility genes: relevance to pathological-signalling cascades,” Neurochemistry International, vol. 52, no. 6, pp. 920–934, 2008. View at: Publisher Site | Google Scholar
  126. K. Honjo, R. van Reekum, and N. P. L. G. Verhoeff, “Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease?” Alzheimer's and Dementia, vol. 5, no. 4, pp. 348–360, 2009. View at: Publisher Site | Google Scholar
  127. R. F. Itzhaki, M. A. Wozniak, D. M. Appelt, and B. J. Balin, “Infiltration of the brain by pathogens causes Alzheimer's disease,” Neurobiology of Aging, vol. 25, no. 5, pp. 619–627, 2004. View at: Publisher Site | Google Scholar
  128. C. J. Carter, “Alzheimer's disease: a pathogenetic autoimmune disorder caused by herpes simplex in a gene-dependent manner,” International Journal of Alzheimer's Disease, vol. 2010, Article ID 140539, 17 pages, 2010. View at: Publisher Site | Google Scholar
  129. S. A. Chance, M. M. Esiri, and T. J. Crow, “Ventricular enlargement in schizophrenia: a primary change in the temporal lobe?” Schizophrenia Research, vol. 62, no. 1-2, pp. 123–131, 2003. View at: Publisher Site | Google Scholar
  130. W. Hennah and D. Porteous, “The DISC1 pathway modulates expression of neurodevelopmental, synaptogenic and sensory perception genes,” PLoS One, vol. 4, no. 3, Article ID e4906, 2009. View at: Publisher Site | Google Scholar
  131. L. Desbonnet, J. L. Waddington, and C. M. P. O'Tuathaigh, “Mutant models for genes associated with schizophrenia,” Biochemical Society Transactions, vol. 37, no. 1, pp. 308–312, 2009. View at: Publisher Site | Google Scholar
  132. H. Jaaro-Peled, “Gene models of schizophrenia: DISC1 mouse models,” Progress in Brain Research, vol. 179, pp. 75–86, 2009. View at: Google Scholar
  133. N. Sakae, N. Yamasaki, K. Kitaichi et al., “Mice lacking the schizophrenia-associated protein FEZ1 manifest hyperactivity and enhanced responsiveness to psychostimulants,” Human Molecular Genetics, vol. 17, no. 20, pp. 3191–3203, 2008. View at: Publisher Site | Google Scholar
  134. C. S. Barros, B. Calabrese, P. Chamero et al., “Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 11, pp. 4507–4512, 2009. View at: Publisher Site | Google Scholar
  135. D. Babovic, C. M. O'Tuathaigh, A. M. O'Connor et al., “Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase,” Neuroscience, vol. 155, no. 4, pp. 1021–1029, 2008. View at: Publisher Site | Google Scholar
  136. W. W. Eaton, M. Byrne, H. Ewald et al., “Association of schizophrenia and autoimmune diseases: linkage of Danish national registers,” American Journal of Psychiatry, vol. 163, no. 3, pp. 521–528, 2006. View at: Publisher Site | Google Scholar
  137. H. Rosenmann, N. Grigoriadis, D. Karussis et al., “Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein,” Archives of Neurology, vol. 63, no. 10, pp. 1459–1467, 2006. View at: Publisher Site | Google Scholar
  138. J. E. Black, I. M. Kodish, A. W. Grossman et al., “Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia,” American Journal of Psychiatry, vol. 161, no. 4, pp. 742–744, 2004. View at: Publisher Site | Google Scholar
  139. N. S. Kolomeets and N. A. Uranova, “Synaptic contacts in schizophrenia: the study with immunocytochemical identification of dopaminergic neurons [Sinapticheskie kontakty pri shizofrenii: issledovaniie s immunotsitokhimicheskoi identifikatsiei dofaminergicheskikh neironov],” Zhurnal Nevropatolgii i Psikhiatrii im. S S Korsakova, vol. 97, no. 12, pp. 39–43, 1997. View at: Google Scholar
  140. P. M. Thompson, C. Vidal, J. N. Giedd et al., “Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 20, pp. 11650–11655, 2001. View at: Publisher Site | Google Scholar
  141. T. A. Bayer, R. Buslei, L. Havas, and P. Falkai, “Evidence for activation of microglia in patients with psychiatric illnesses,” Neuroscience Letters, vol. 271, no. 2, pp. 126–128, 1999. View at: Publisher Site | Google Scholar
  142. R. J. Holden and I. S. Pakula, “Immunological influences in attention-deficit disorder and schizophrenia: is there a link between these two conditions?” Medical Hypotheses, vol. 45, no. 6, pp. 575–587, 1995. View at: Publisher Site | Google Scholar
  143. J. Söderlund, J. Schröder, C. Nordin et al., “Activation of brain interleukin-1β in schizophrenia,” Molecular Psychiatry, vol. 14, no. 12, pp. 1069–1071, 2009. View at: Publisher Site | Google Scholar
  144. Ł. Drzyzga, E. Obuchowicz, A. Marcinowska, and Z. S. Herman, “Cytokines in schizophrenia and the effects of antipsychotic drugs,” Brain, Behavior, and Immunity, vol. 20, no. 6, pp. 532–545, 2006. View at: Publisher Site | Google Scholar
  145. R. S. Smith and M. Maes, “The macrophage-T-lymphocyte theory of schizophrenia: additional evidence,” Medical Hypotheses, vol. 45, no. 2, pp. 135–141, 1995. View at: Publisher Site | Google Scholar
  146. M. P. Vawter, O. Dillon-Carter, F. Issa, R. J. Wyatt, and W. J. Freed, “Transforming growth factors β1 and β2 in the cerebrospinal fluid of chronic schizophrenic patients,” Neuropsychopharmacology, vol. 16, no. 1, pp. 83–87, 1997. View at: Publisher Site | Google Scholar
  147. R. Rajapakse, B. Uring-Lambert, K. L. Andarawewa et al., “1,25(OH)2D3 inhibits in vitro and in vivo intracellular growth of apicomplexan parasite Toxoplasma gondii,” Journal of Steroid Biochemistry and Molecular Biology, vol. 103, no. 3-5, pp. 811–814, 2007. View at: Publisher Site | Google Scholar
  148. J. J. McGrath, D. W. Eyles, C. B. Pedersen et al., “Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study,” Archives of General Psychiatry, vol. 67, no. 9, pp. 889–894, 2010. View at: Publisher Site | Google Scholar
  149. D. Kanduc, A. Stufano, G. Lucchese, and A. Kusalik, “Massive peptide sharing between viral and human proteomes,” Peptides, vol. 29, no. 10, pp. 1755–1766, 2008. View at: Publisher Site | Google Scholar
  150. D. E. Dietrich and L. Bode, “Human Borna disease virus-infection and its therapy in affective disorders,” APMIS, vol. 116, no. 124, pp. 61–65, 2008. View at: Publisher Site | Google Scholar
  151. E. Fazzini, J. Fleming, and S. Fahn, “Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease,” Movement Disorders, vol. 7, no. 2, pp. 153–158, 1992. View at: Google Scholar
  152. B. A. Bagert, “Epstein-Barr virus in multiple sclerosis,” Current Neurology and Neuroscience Reports, vol. 9, no. 5, pp. 405–410, 2009. View at: Publisher Site | Google Scholar

Copyright © 2011 C. J. Carter. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

9872 Views | 1344 Downloads | 16 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder